Homegrown specialty pharmaceutical company iX Biopharma Ltd. (iX Biopharma) has announced that it has been granted a patent in Canada (no. 2777218) for its WaferiX drug delivery technology. Canada has a potential market size of C$515 million and C$97 million for opioids and sleep aids, according to Patented Medicine Prices Review Board of Canada and Euromonitor respectively.

The Group has also been granted a patent in South Korea this year, while counterpart patents were granted in Australia, Indonesia, Japan, Malaysia, New Zealand and Singapore prior to that.

The grant of the Canadian patent, which expires on 26 October 2030, marks another milestone for iX Biopharma, following the positive results received in September 2016 from its bioequivalence study for PheoniX, a drug for the treatment of male erectile dysfunction.